Revisión web de agenusbio.com
Agenus: Better immunotherapies
Generado el 28 Marzo 2026 02:34 AM
Resultados antiguos? ACTUALIZAR !
La puntuación es 54/100
Contenido SEO
Título
Agenus: Better immunotherapies
Longitud : 30
Perfecto, tu título contiene entre 10 y 70 caracteres.
Descripción
Activating the Power of the Immune System to Defeat Cancer
Longitud : 58
Preferiblemente tu descripción meta debe contener entre 70 y 160 caracteres (espacios incluidos). Usa esta herramienta gratuita para calcular la longitu del texto.
Palabras Claves (Keywords)
Muy mal. No hemos encontrado palabras clave (meta keywords) en tu página. Usa este generador de meta tags gratuito para crear tus palabras clave.
Propiedades Meta Og
Bien. Tu página usa propiedades Og (etiquetas og).
| Propiedad | Contenido |
|---|---|
| type | website |
Titulos
| H1 | H2 | H3 | H4 | H5 | H6 |
| 2 | 24 | 65 | 0 | 0 | 0 |
- [H1] Using Your Immune System to Defeat Cancer
- [H1] Using Your Immune System to Defeat Cancer
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
- [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
- [H2] Innovative Immunotherapies
- [H2] Learn how our science is changing what’s possible
- [H2] Stage III MSS Colorectal Cancer
- [H2] Merkel Cell Carcinoma
- [H2] Undifferentiated Pleomorphic Sarcoma
- [H2] Bringing the Power of Immunotherapy to More Patients
- [H2] “30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
- [H2] In the News
- [H2] Get answers about clinical trials, patient access, and more
- [H2] By the Numbers
- [H3] OncoDaily
- [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
- [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
- [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
- [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
- [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
- [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
- [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
- [H3] Redefining Cancer Care
- [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
- [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
- [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
- [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
- [H3] Immunotherapies break into cold colorectal cancers at ASCO
- [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
- [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
- [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
- [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
- [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
- [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
- [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
- [H3] New Strategies for Targeting CTLA-4 Emerge
- [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
- [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
- [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
- [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
- [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
- [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
- [H3] Unpacking the Latest Research in Gastrointestinal Cancers
- [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
- [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
- [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
- [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
- [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
- [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
- [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
- [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
- [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
- [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
- [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
- [H3] Redefining Cancer Care
- [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
- [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
- [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
- [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
- [H3] Immunotherapies break into cold colorectal cancers at ASCO
- [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
- [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
- [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
- [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
- [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
- [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
- [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
- [H3] New Strategies for Targeting CTLA-4 Emerge
- [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
- [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
- [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
- [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
- [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
- [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
- [H3] Unpacking the Latest Research in Gastrointestinal Cancers
- [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
- [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
- [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
- [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
Imagenes
Hemos encontrado 164 imágenes en esta web.
164 atributos alt están vacios o no existen. Agrega texto alternativo para que los motores de búsqueda puedan entender las imágenes.
Ratio Texto/HTML
Ratio : 5%
El ratio entre texto y código HTML de esta página es menor que el 15 por ciento, esto significa que tu web posiblemente necesite más contenido en texto.
Flash
Perfecto, no se ha detectado contenido Flash en la página.
Iframe
Muy mal, tienes Iframes en la página, esto significa que el contenido no podrá ser indexado.
Enlaces SEO
Reescritura URL
Bien. Tus enlaces parecen amigables
Guiones bajos en las URLs
Perfecto! No hemos detectado guiones bajos en tus URLs
Enlaces en página
Hemos encontrado un total de 41 enlaces incluyendo 0 enlace(s) a ficheros
| Ancla | Tipo | Jugo |
|---|---|---|
| - | Interna | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| - | Externo | Pasando Jugo |
| Opt-out preferences | Interna | Pasando Jugo |
| Terms and Conditions of Use | Interna | Pasando Jugo |
| Privacy Policy | Interna | Pasando Jugo |
| Community Guidelines | Interna | Pasando Jugo |
| Access to Investigational Medicines Policy | Interna | Pasando Jugo |
| Report Adverse Event | Interna | Pasando Jugo |
| Investor Portal | Interna | Pasando Jugo |
Palabras Clave SEO
Nube de Palabras Clave
cancer botensilimab colorectal balstilimab immunotherapy news january access agenus patient
Consistencia de las Palabras Clave
| Palabra Clave (Keyword) | Contenido | Título | Palabras Claves (Keywords) | Descripción | Titulos |
|---|---|---|---|---|---|
| cancer | 48 |  |
|
 |
|
| access | 29 | |
|
|
|
| botensilimab | 28 | |
|
|
|
| agenus | 25 | |
|
|
|
| colorectal | 23 | |
|
|
|
Usabilidad
Url
Dominio : agenusbio.com
Longitud : 13
Favicon
Genial, tu web tiene un favicon.
Imprimibilidad
No hemos encontrado una hoja de estilos CSS para impresión.
Idioma
Genial. Has declarado el idioma en.
Dublin Core
Esta página no usa Dublin Core.
Documento
Tipo de documento (Doctype)
HTML 5
Codificación
Perfecto. Has declarado como codificación UTF-8.
Validez W3C
Errores : 0
Avisos : 0
Privacidad de los Emails
Atención! Hemos encontrado por lo menos una dirección de correo electrónico en texto plano. Usa este protector antispam gratuito para ocultarla de los spammers.
HTML obsoleto
Genial, no hemos detectado ninguna etiqueta HTML obsoleta.
Consejos de Velocidad
|
Excelente, esta web no usa tablas. |
|
Muy mal, tu web está usando estilos embenidos (inline CSS). |
|
Genial, tu página web usa muy pocos ficheros CSS. |
|
Muy mal, tu sitio usa demasiados ficheros JavaScript (más de 6). |
|
Su sitio web se beneficia del tipo de compresión gzip. ¡Perfecto! |
Movil
Optimización Móvil
|
Icono para Apple |
|
Etiqueta Meta Viewport |
|
Contenido Flash |
Optimización
Mapa del sitio XML
¡Perfecto! Su sitio tiene un mapa del sitio en XML.
| https://www.agenusbio.com/sitemap.xml |
Robots.txt
https://agenusbio.com/robots.txt
¡Estupendo! Su sitio web tiene un archivo robots.txt.
Herramientas de Analítica
No disponible
No hemos encontrado ninguna herramienta de analítica en esta web.
La analítica Web le permite medir la actividad de los visitantes de su sitio web. Debería tener instalada al menos una herramienta de analítica y se recomienda instalar otra más para obtener una confirmación de los resultados.
PageSpeed Insights
Dispositivo
Categorias
Free SEO Testing Tool
Free SEO Testing Tool es una herramienta seo gratuita que te ayuda a analizar tu web